Growth Hormone Therapy Benefits Pituitary Stalk Interruption Syndrome Patients with Short Stature: A Retrospective Study of 75 Han Chinese
Objective. We aim to investigate the long-term benefits of growth hormone (GH) therapy in short stature adolescents and adults with pituitary stalk interruption syndrome (PSIS), which would be beneficial for future clinical applications. Design and Methods. In this study, initial height, final heigh...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | International Journal of Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2016/1896285 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849395916713230336 |
|---|---|
| author | Cheng-Zhi Wang Ling-Ling Guo Bai-Yu Han An-Ping Wang Hong-Yan Liu Xing Su Qing-Hua Guo Yi-Ming Mu |
| author_facet | Cheng-Zhi Wang Ling-Ling Guo Bai-Yu Han An-Ping Wang Hong-Yan Liu Xing Su Qing-Hua Guo Yi-Ming Mu |
| author_sort | Cheng-Zhi Wang |
| collection | DOAJ |
| description | Objective. We aim to investigate the long-term benefits of growth hormone (GH) therapy in short stature adolescents and adults with pituitary stalk interruption syndrome (PSIS), which would be beneficial for future clinical applications. Design and Methods. In this study, initial height, final height, total height gain, and GH treatment history were retrospectively investigated in 75 Chinese PSIS patients. We compared height gain between the GH treated cohort and untreated cohort and explored the impact of different GH therapy duration on height gain. Results. For GH treated patients, their final height (SDS) increased from -1.99±1.91 (−6.93~2.80) at bone age (BA) of 11.2 (5.0~17.0) years to -1.47±1.64 (−7.82~1.05) at BA of 16.6 (8.0~18.0) years (P=0.016). And GH treated patients had more height gain than the untreated patients (P<0.05). There was a significant difference between the different GH therapy duration groups (P=0.001): GH 0 versus GH 3, P=0.000; GH 1 versus GH 3, P=0.028; GH 2 versus GH 3, P=0.044. Conclusion. Adult Chinese PSIS patients with short stature benefited the most from at least 12 months of GH therapy. Although patient diagnosis age was lagged behind in the developing countries, GH treatment was still effective for them and resulted in a higher final height and more height gain. |
| format | Article |
| id | doaj-art-b72e16786ea14891996fd2d0af7bb6ec |
| institution | Kabale University |
| issn | 1687-8337 1687-8345 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Endocrinology |
| spelling | doaj-art-b72e16786ea14891996fd2d0af7bb6ec2025-08-20T03:39:28ZengWileyInternational Journal of Endocrinology1687-83371687-83452016-01-01201610.1155/2016/18962851896285Growth Hormone Therapy Benefits Pituitary Stalk Interruption Syndrome Patients with Short Stature: A Retrospective Study of 75 Han ChineseCheng-Zhi Wang0Ling-Ling Guo1Bai-Yu Han2An-Ping Wang3Hong-Yan Liu4Xing Su5Qing-Hua Guo6Yi-Ming Mu7Department of Endocrinology, Chinese PLA General Hospital, Beijing 100853, ChinaDepartment of Endocrinology, Chinese PLA General Hospital, Beijing 100853, ChinaDepartment of Endocrinology, Chinese PLA General Hospital, Beijing 100853, ChinaDepartment of Endocrinology, Chinese PLA General Hospital, Beijing 100853, ChinaDepartment of Endocrinology, Chinese PLA General Hospital, Beijing 100853, ChinaDepartment of Endocrinology, Chinese PLA General Hospital, Beijing 100853, ChinaDepartment of Endocrinology, Chinese PLA General Hospital, Beijing 100853, ChinaDepartment of Endocrinology, Chinese PLA General Hospital, Beijing 100853, ChinaObjective. We aim to investigate the long-term benefits of growth hormone (GH) therapy in short stature adolescents and adults with pituitary stalk interruption syndrome (PSIS), which would be beneficial for future clinical applications. Design and Methods. In this study, initial height, final height, total height gain, and GH treatment history were retrospectively investigated in 75 Chinese PSIS patients. We compared height gain between the GH treated cohort and untreated cohort and explored the impact of different GH therapy duration on height gain. Results. For GH treated patients, their final height (SDS) increased from -1.99±1.91 (−6.93~2.80) at bone age (BA) of 11.2 (5.0~17.0) years to -1.47±1.64 (−7.82~1.05) at BA of 16.6 (8.0~18.0) years (P=0.016). And GH treated patients had more height gain than the untreated patients (P<0.05). There was a significant difference between the different GH therapy duration groups (P=0.001): GH 0 versus GH 3, P=0.000; GH 1 versus GH 3, P=0.028; GH 2 versus GH 3, P=0.044. Conclusion. Adult Chinese PSIS patients with short stature benefited the most from at least 12 months of GH therapy. Although patient diagnosis age was lagged behind in the developing countries, GH treatment was still effective for them and resulted in a higher final height and more height gain.http://dx.doi.org/10.1155/2016/1896285 |
| spellingShingle | Cheng-Zhi Wang Ling-Ling Guo Bai-Yu Han An-Ping Wang Hong-Yan Liu Xing Su Qing-Hua Guo Yi-Ming Mu Growth Hormone Therapy Benefits Pituitary Stalk Interruption Syndrome Patients with Short Stature: A Retrospective Study of 75 Han Chinese International Journal of Endocrinology |
| title | Growth Hormone Therapy Benefits Pituitary Stalk Interruption Syndrome Patients with Short Stature: A Retrospective Study of 75 Han Chinese |
| title_full | Growth Hormone Therapy Benefits Pituitary Stalk Interruption Syndrome Patients with Short Stature: A Retrospective Study of 75 Han Chinese |
| title_fullStr | Growth Hormone Therapy Benefits Pituitary Stalk Interruption Syndrome Patients with Short Stature: A Retrospective Study of 75 Han Chinese |
| title_full_unstemmed | Growth Hormone Therapy Benefits Pituitary Stalk Interruption Syndrome Patients with Short Stature: A Retrospective Study of 75 Han Chinese |
| title_short | Growth Hormone Therapy Benefits Pituitary Stalk Interruption Syndrome Patients with Short Stature: A Retrospective Study of 75 Han Chinese |
| title_sort | growth hormone therapy benefits pituitary stalk interruption syndrome patients with short stature a retrospective study of 75 han chinese |
| url | http://dx.doi.org/10.1155/2016/1896285 |
| work_keys_str_mv | AT chengzhiwang growthhormonetherapybenefitspituitarystalkinterruptionsyndromepatientswithshortstaturearetrospectivestudyof75hanchinese AT linglingguo growthhormonetherapybenefitspituitarystalkinterruptionsyndromepatientswithshortstaturearetrospectivestudyof75hanchinese AT baiyuhan growthhormonetherapybenefitspituitarystalkinterruptionsyndromepatientswithshortstaturearetrospectivestudyof75hanchinese AT anpingwang growthhormonetherapybenefitspituitarystalkinterruptionsyndromepatientswithshortstaturearetrospectivestudyof75hanchinese AT hongyanliu growthhormonetherapybenefitspituitarystalkinterruptionsyndromepatientswithshortstaturearetrospectivestudyof75hanchinese AT xingsu growthhormonetherapybenefitspituitarystalkinterruptionsyndromepatientswithshortstaturearetrospectivestudyof75hanchinese AT qinghuaguo growthhormonetherapybenefitspituitarystalkinterruptionsyndromepatientswithshortstaturearetrospectivestudyof75hanchinese AT yimingmu growthhormonetherapybenefitspituitarystalkinterruptionsyndromepatientswithshortstaturearetrospectivestudyof75hanchinese |